Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients.

Lin RY, Argenta PA, Sullivan KM, Adzick NS.

Clin Cancer Res. 1995 Mar;1(3):327-31.

2.

Urinary hyaluronic acid is a Wilms' tumor marker.

Lin RY, Argenta PA, Sullivan KM, Stern R, Adzick NS.

J Pediatr Surg. 1995 Feb;30(2):304-8.

PMID:
7738755
3.

Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers.

Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J.

J Natl Cancer Inst. 1994 Mar 2;86(5):356-61.

PMID:
7508518
4.
5.

Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?

Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, Leverger G, Dosquet C.

Clin Cancer Res. 2001 Mar;7(3):538-43.

6.

Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.

Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N.

Klin Padiatr. 2004 May-Jun;216(3):132-40.

PMID:
15175957
7.

Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.

Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ.

Cancer Res. 2001 Mar 15;61(6):2533-6.

8.

Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.

Kurschat P, Eming S, Nashan D, Krieg T, Mauch C.

Br J Dermatol. 2007 Apr;156(4):653-8. Epub 2007 Jan 30.

PMID:
17263813
9.

Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.

Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA.

Eur J Haematol. 2004 Apr;72(4):252-8.

PMID:
15089762
10.

Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma.

Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W.

J Cancer Res Clin Oncol. 1999 Oct;125(10):577-81.

PMID:
10473871
11.

Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma.

Colomer R, Aparicio J, Montero S, Guzmán C, Larrodera L, Cortés-Funes H.

Br J Cancer. 1997;76(9):1215-20.

12.

Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy.

O'Brien TS, Smith K, Cranston D, Fuggle S, Bicknell R, Harris AL.

Br J Urol. 1995 Sep;76(3):311-4.

PMID:
7551838
13.

Is partial nephrectomy appropriate treatment for unilateral Wilms' tumor?

Moorman-Voestermans CG, Aronson DC, Staalman CR, Delemarre JF, de Kraker J.

J Pediatr Surg. 1998 Feb;33(2):165-70.

PMID:
9498380
14.

Hyaluronidase levels in urine from Wilms' tumor patients.

Stern M, Longaker MT, Adzick NS, Harrison MR, Stern R.

J Natl Cancer Inst. 1991 Nov 6;83(21):1569-74.

PMID:
1660075
16.

Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels.

Horstmann M, Merseburger AS, von der Heyde E, Serth J, Wegener G, Mengel M, Feil G, Hennenlotter J, Nagele U, Anastasiadis A, Bokemeyer C, Stenzl A, Kuczyk M.

J Cancer Res Clin Oncol. 2005 Nov;131(11):715-22. Epub 2005 Nov 1.

PMID:
16080018
17.

[Treatment of advanced Wilms' tumor].

Li MJ, Huang Y, Tang DX, Zhou YB, Tang HF, Liang JF.

Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):791-5. Chinese.

PMID:
17366799
18.

Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.

Safford SD, Freemerman AJ, Langdon S, Bentley R, Goyeau D, Grundy PE, Skinner MA.

J Pediatr Surg. 2005 Feb;40(2):341-8.

PMID:
15750927
19.

High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.

Ruotsalainen T, Joensuu H, Mattson K, Salven P.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1492-5.

20.

Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients.

Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL.

Anticancer Res. 2000 Mar-Apr;20(2B):1189-94.

PMID:
10810420

Supplemental Content

Support Center